Initial report of 3rd line combination chemotherapy comprising gemcitabine, cisplatin and paclitaxel for advanced germ cell carcinoma

Takashi Saika, Kohei Edamura, Makoto Kobuke, Tatsuya Uesugi, Yasuyuki Kobayashi, Akira Takao, Haruki Kaku, Yasutomo Nasu, Hiromi Kumon

Research output: Contribution to journalArticle

Abstract

Only 20-30% of patients with refractory or recurrent germ cell tumors (GCT) are cured by salvage chemotherapy. Gemcitabine (GEM) and Paclitaxel (PTX) are potent anticancer agents against a variety of solid cancers. The current pilot study investigated the efficacy of third-line and/or salvage combination chemotherapy comprising GEM, PTX and cisplatin (CDDP) for refractory and/or conventional chemotherapy-resistant GCT. The combination chemotherapy consisted of 800 mg/m2 GEM, 80 mg/m2 PTX and 50 mg/m2 on Days 1 and 15, every 3 weeks. A total of five patients, 3 with refractory GCT, one with progressing extragonadal GCT and one with viable cancer cells in the specimen of RPLND received 2-3 cycles of the combination chemotherapy. Four of the patients were assessed for response, and all the patients were assessed for toxicity. The response rate was 75% (partial response). Two of these patients underwent radiation therapy and surgical resection after the chemotherapy, and they continue to show no evidence of disease. However, one patient died of the disease. One patient who received the chemotherapy as an adjuvant therapy remains alive without recurrence. Myelosuppression was the major toxicity, but this was manageable. Gastrointestinal complications were very mild in comparison with other chemotherapies. This pilot study demonstrates that the chemotherapy showed an anticancer activity for patients with refractory GCT, without any serious side effects. Although this study comprised only a few patients, these findings suggest that combination chemotherapy may be one of the options of salvage chemotherapy for patients with refractory and/or conventional chemotherapy-resistant GCT. (Nishinihon J. Urol. 71: 202-207,2009).

Original languageEnglish
Pages (from-to)202-207
Number of pages6
JournalNishinihon Journal of Urology
Volume71
Issue number5
Publication statusPublished - May 2009

Fingerprint

gemcitabine
Combination Drug Therapy
Germ Cells
Germ Cell and Embryonal Neoplasms
Carcinoma
Drug Therapy
Paclitaxel
TP protocol
Adjuvant Chemotherapy

Keywords

  • Chemotherapy
  • Gemcitabine
  • Germ cell carcinoma
  • Paclitaxel
  • Salvage therapy

ASJC Scopus subject areas

  • Urology

Cite this

Initial report of 3rd line combination chemotherapy comprising gemcitabine, cisplatin and paclitaxel for advanced germ cell carcinoma. / Saika, Takashi; Edamura, Kohei; Kobuke, Makoto; Uesugi, Tatsuya; Kobayashi, Yasuyuki; Takao, Akira; Kaku, Haruki; Nasu, Yasutomo; Kumon, Hiromi.

In: Nishinihon Journal of Urology, Vol. 71, No. 5, 05.2009, p. 202-207.

Research output: Contribution to journalArticle

@article{d182d0f6f8f34421ab3d05d23f7ea2e7,
title = "Initial report of 3rd line combination chemotherapy comprising gemcitabine, cisplatin and paclitaxel for advanced germ cell carcinoma",
abstract = "Only 20-30{\%} of patients with refractory or recurrent germ cell tumors (GCT) are cured by salvage chemotherapy. Gemcitabine (GEM) and Paclitaxel (PTX) are potent anticancer agents against a variety of solid cancers. The current pilot study investigated the efficacy of third-line and/or salvage combination chemotherapy comprising GEM, PTX and cisplatin (CDDP) for refractory and/or conventional chemotherapy-resistant GCT. The combination chemotherapy consisted of 800 mg/m2 GEM, 80 mg/m2 PTX and 50 mg/m2 on Days 1 and 15, every 3 weeks. A total of five patients, 3 with refractory GCT, one with progressing extragonadal GCT and one with viable cancer cells in the specimen of RPLND received 2-3 cycles of the combination chemotherapy. Four of the patients were assessed for response, and all the patients were assessed for toxicity. The response rate was 75{\%} (partial response). Two of these patients underwent radiation therapy and surgical resection after the chemotherapy, and they continue to show no evidence of disease. However, one patient died of the disease. One patient who received the chemotherapy as an adjuvant therapy remains alive without recurrence. Myelosuppression was the major toxicity, but this was manageable. Gastrointestinal complications were very mild in comparison with other chemotherapies. This pilot study demonstrates that the chemotherapy showed an anticancer activity for patients with refractory GCT, without any serious side effects. Although this study comprised only a few patients, these findings suggest that combination chemotherapy may be one of the options of salvage chemotherapy for patients with refractory and/or conventional chemotherapy-resistant GCT. (Nishinihon J. Urol. 71: 202-207,2009).",
keywords = "Chemotherapy, Gemcitabine, Germ cell carcinoma, Paclitaxel, Salvage therapy",
author = "Takashi Saika and Kohei Edamura and Makoto Kobuke and Tatsuya Uesugi and Yasuyuki Kobayashi and Akira Takao and Haruki Kaku and Yasutomo Nasu and Hiromi Kumon",
year = "2009",
month = "5",
language = "English",
volume = "71",
pages = "202--207",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "5",

}

TY - JOUR

T1 - Initial report of 3rd line combination chemotherapy comprising gemcitabine, cisplatin and paclitaxel for advanced germ cell carcinoma

AU - Saika, Takashi

AU - Edamura, Kohei

AU - Kobuke, Makoto

AU - Uesugi, Tatsuya

AU - Kobayashi, Yasuyuki

AU - Takao, Akira

AU - Kaku, Haruki

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

PY - 2009/5

Y1 - 2009/5

N2 - Only 20-30% of patients with refractory or recurrent germ cell tumors (GCT) are cured by salvage chemotherapy. Gemcitabine (GEM) and Paclitaxel (PTX) are potent anticancer agents against a variety of solid cancers. The current pilot study investigated the efficacy of third-line and/or salvage combination chemotherapy comprising GEM, PTX and cisplatin (CDDP) for refractory and/or conventional chemotherapy-resistant GCT. The combination chemotherapy consisted of 800 mg/m2 GEM, 80 mg/m2 PTX and 50 mg/m2 on Days 1 and 15, every 3 weeks. A total of five patients, 3 with refractory GCT, one with progressing extragonadal GCT and one with viable cancer cells in the specimen of RPLND received 2-3 cycles of the combination chemotherapy. Four of the patients were assessed for response, and all the patients were assessed for toxicity. The response rate was 75% (partial response). Two of these patients underwent radiation therapy and surgical resection after the chemotherapy, and they continue to show no evidence of disease. However, one patient died of the disease. One patient who received the chemotherapy as an adjuvant therapy remains alive without recurrence. Myelosuppression was the major toxicity, but this was manageable. Gastrointestinal complications were very mild in comparison with other chemotherapies. This pilot study demonstrates that the chemotherapy showed an anticancer activity for patients with refractory GCT, without any serious side effects. Although this study comprised only a few patients, these findings suggest that combination chemotherapy may be one of the options of salvage chemotherapy for patients with refractory and/or conventional chemotherapy-resistant GCT. (Nishinihon J. Urol. 71: 202-207,2009).

AB - Only 20-30% of patients with refractory or recurrent germ cell tumors (GCT) are cured by salvage chemotherapy. Gemcitabine (GEM) and Paclitaxel (PTX) are potent anticancer agents against a variety of solid cancers. The current pilot study investigated the efficacy of third-line and/or salvage combination chemotherapy comprising GEM, PTX and cisplatin (CDDP) for refractory and/or conventional chemotherapy-resistant GCT. The combination chemotherapy consisted of 800 mg/m2 GEM, 80 mg/m2 PTX and 50 mg/m2 on Days 1 and 15, every 3 weeks. A total of five patients, 3 with refractory GCT, one with progressing extragonadal GCT and one with viable cancer cells in the specimen of RPLND received 2-3 cycles of the combination chemotherapy. Four of the patients were assessed for response, and all the patients were assessed for toxicity. The response rate was 75% (partial response). Two of these patients underwent radiation therapy and surgical resection after the chemotherapy, and they continue to show no evidence of disease. However, one patient died of the disease. One patient who received the chemotherapy as an adjuvant therapy remains alive without recurrence. Myelosuppression was the major toxicity, but this was manageable. Gastrointestinal complications were very mild in comparison with other chemotherapies. This pilot study demonstrates that the chemotherapy showed an anticancer activity for patients with refractory GCT, without any serious side effects. Although this study comprised only a few patients, these findings suggest that combination chemotherapy may be one of the options of salvage chemotherapy for patients with refractory and/or conventional chemotherapy-resistant GCT. (Nishinihon J. Urol. 71: 202-207,2009).

KW - Chemotherapy

KW - Gemcitabine

KW - Germ cell carcinoma

KW - Paclitaxel

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=67949100660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67949100660&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 202

EP - 207

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 5

ER -